|
1
|
Hara Y: Advances in Food Science and
Technology. Nippon shokuhin Kogyo Gakkai; Korin, Tokyo: 1990
|
|
2
|
Kuriyama S, Shimazu T, Ohmori K, Kikuchi
N, Nakaya N, Nishino Y, Tsubono Y and Tsuji I: Green tea
consumption and mortality due to cardiovascular disease, cancer,
and all causes in Japan: The Ohsaki study. JAMA. 296:1255–1265.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shixian Q, VanCrey B, Shi J, Kakuda Y and
Jiang Y: Green tea extract thermogenesis-induced weight loss by
epigallocat-echin gallate inhibition of
catechol-O-methyltransferase. J Med Food. 9:451–458. 2006.
View Article : Google Scholar
|
|
4
|
Nakazato T, Ito K, Miyakawa Y, Kinjo K,
Yamada T, Hozumi N, Ikeda Y and Kizaki M: Catechin, a green tea
component, rapidly induces apoptosis of myeloid leukemic cells via
modulation of reactive oxygen species production in vitro and
inhibits tumor growth in vivo. Haematologica. 90:317–325.
2005.PubMed/NCBI
|
|
5
|
Bettuzzi S, Brausi M, Rizzi F, Castagnetti
G, Peracchia G and Corti A: Chemoprevention of human prostate
cancer by oral administration of green tea catechins in volunteers
with high-grade prostate intraepithelial neoplasia: A preliminary
report from a one-year proof-of-principle study. Cancer Res.
66:1234–1240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu JW, Makey KL, Tucker KB, Chinchar E,
Mao X, Pei I, Thomas EY and Miele L: EGCG, a major green tea
catechin suppresses breast tumor angiogenesis and growth via
inhibiting the activation of HIF-1α and NFκB, and VEGF expression.
Vasc Cell. 5:92013. View Article : Google Scholar
|
|
7
|
Lecumberri E, Dupertuis YM, Miralbell R
and Pichard C: Green tea polyphenol epigallocatechin-3-gallate
(EGCG) as adjuvant in cancer therapy. Clin nutr. 32:894–903. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qiao J, Gu C, shang W, Du J, Yin W, Zhu M,
Wang W, Han M and Lu W: Effect of green tea on pharmacokinetics of
5-fluorouracil in rats and pharmacodynamics in human cell lines in
vitro. Food Chem Toxicol. 49:1410–1415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang G, Tang A, Lin X, Li L, Zhang S,
Huang Z, Tang H and Li QQ: Green tea catechins augment the
antitumor activity of doxorubicin in an in vivo mouse model for
chemoresistant liver cancer. Int J Oncol. 37:111–123.
2010.PubMed/NCBI
|
|
10
|
Farabegoli F, Papi A and Orlandi M:
(−)-Epigallocatechin-3-gallate down-regulates EGfr, MMP-2, MMP-9
and EMMPrIn and inhibits the invasion of MCf-7 tamoxifen-resistant
cells. Biosci Rep. 31:99–108. 2011. View Article : Google Scholar
|
|
11
|
Luo KW, Ko CH, Yue GGL, Lee JKM, Li KK,
Lee M, Li G, Fung KP, Leung PC and Lau CB: Green tea (Camellia
sinensis) extract inhibits both the metastasis and osteolytic
components of mammary cancer 4T1 lesions in mice. J Nutr Biochem.
25:395–403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Labrinidis A, Hay S, liapis V, findlay DM
and Evdokiou A: Zoledronic acid protects against
osteosarcoma-induced bone destruction but lacks efficacy against
pulmonary metastases in a syngeneic rat model. Int J Cancer.
127:345–354. 2010.
|
|
13
|
Senaratne SG and Colston KW: Direct
effects of bisphosphonates on breast cancer cells. Breast Cancer
Res. 4:18–23. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Evdokiou A, Labrinidis A, Bouralexis S,
Hay S and Findlay DM: Induction of cell death of human osteogenic
sarcoma cells by zoledronic acid resembles anoikis. Bone.
33:216–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wood J, Bonjean K, Ruetz S, Bellahcène A,
Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic
effects of the bisphosphonate compound zoledronic acid. J Pharmacol
Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao X, Xu X, Guo L, et al: Biomarker
alterations with metronomic use of low-dose zoledronic acid for
breast cancer patients with bone metastases and potential clinical
significance. Breast Cancer Res Treat. 124:733–743. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang
J, Wang B, Wang Z and Hu X: Prognostic and predictive value of
clinical and biochemical factors in breast cancer patients with
bone metastases receiving ‘metronomic’ zoledronic acid. BMC Cancer.
11:4032011. View Article : Google Scholar
|
|
18
|
Daubiné F, Le Gall C, Gasser J, Green J
and Clézardin P: Antitumor effects of clinical dosing regimens of
bisphosphonates in experimental breast cancer bone metastasis. J
Natl Cancer Inst. 99:322–330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Facchini G, Caraglia M, Morabito A, et al:
Metronomic administration of zoledronic acid and taxotere
combination in castration resistant prostate cancer patients: Phase
I ZANTE trial. Cancer Biol Ther. 10:543–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo KW, Ko CH, Yue GGL, et al: Anti-tumor
and anti-osteolysis effects of the metronomic use of zoledronic
acid in primary and metastatic breast cancer mouse models. Cancer
Lett. 339:42–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng L, Song XH, Shi XG, Li JX and Ye CX:
An improved HPLC method for simultaneous determination of phenolic
compounds, purine alkaloids and theanine in Camellia species. J
Food Compos Anal. 21:559–563. 2008. View Article : Google Scholar
|
|
22
|
Staibano S, Lo Muzio L, Mezza E,
argenziano G, Tornillo L, Pannone G and De Rosa G: Prognostic value
of apoptotic index in cutaneous basal cell carcinomas of head and
neck. Oral Oncol. 35:541–547. 1999. View Article : Google Scholar
|
|
23
|
Vigl B, Zgraggen C, Rehman N,
Banziger-Tobler NE, Detmar M and Halin C: Coxsackie- and adenovirus
receptor (CAR) is expressed in lymphatic vessels in human skin and
affects lymphatic endothelial cell function in vitro. Exp Cell Res.
315:336–347. 2009. View Article : Google Scholar
|
|
24
|
Xiao D and Singh SV: Phenethyl
isothiocyanate inhibits angio-genesis in vitro and ex vivo. Cancer
res. 67:2239–2246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Azim HA, Kamal NS and Azim HA Jr: Bone
metastasis in breast cancer: The story of RANK-ligand. J Egypt Natl
Cancer Inst. 24:107–114. 2012. View Article : Google Scholar
|
|
26
|
Chaudhary AK, Pandya S, Ghosh K and
Nadkarni A: Matrix metalloproteinase and its drug targets therapy
in solid and hematological malignancies: An overview. Mutat Res.
753:7–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fitzgerald JB, Schoeberl B, Nielsen UB and
Sorger PK: Systems biology and combination therapy in the quest for
clinical efficacy. Nat Chem Biol. 2:458–466. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeh P and Kishony R: Networks from
drug-drug surfaces. Mol Syst Biol. 3:852007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lam YC, Cheng CW, Peng H, Law CK, Huang X
and Bian Z: Cancer patients’ attitudes towards Chinese medicine: A
Hong Kong survey. Chin Med. 4:252009. View Article : Google Scholar
|
|
30
|
Wang JA, Zhou FX and Zhang ML: Treatment
for advanced gastric cardia carcinoma in 26 cases of integrated
traditional Chinese and Western Medicine. Shanxi J Tradit Chin Med.
25:772–773. 2004.
|
|
31
|
Eliza WL, Fai CK and Chung LP: Efficacy of
Yun zhi (Coriolus versicolor) on survival in cancer patients:
Systematic review and meta-analysis. Recent Pat Inflamm allergy
Drug Discov. 6:78–87. 2012. View Article : Google Scholar
|
|
32
|
Mazumder ME, Beale P, Chan C, Yu JQ and
Huq F: Epigallo-catechin gallate acts synergistically in
combination with cisplatin and designed trans-palladiums in ovarian
cancer cells. Anticancer Res. 32:4851–4860. 2012.PubMed/NCBI
|
|
33
|
Jackman AL, Kaye S and Workman P: The
combination of cytotoxic and molecularly targeted therapies - can
it be done. Drug Discov Today. 1:445–454. 2004.
|
|
34
|
Pulaski BA and Ostrand-Rosenberg S:
Reduction of established spontaneous mammary carcinoma metastases
following immunotherapy with major histocompatibility complex class
II and B7.1 cell-based tumor vaccines. Cancer Res. 58:1486–1493.
1998.PubMed/NCBI
|
|
35
|
Kerr JF, Wyllie AH and Currie AR:
Apoptosis: A basic biological phenomenon with wide-ranging
implications in tissue kinetics. Br J Cancer. 26:239–257. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baliga MS, Meleth S and Katiyar SK: Growth
inhibitory and antimetastatic effect of green tea polyphenols on
metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and
in vivo systems. Clin Cancer Res. 11:1918–1927. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ko CH, lau KM, Choy WY and leung PC:
Effects of tea catechins, epigallocatechin, gallocatechin, and
gallocatechin gallate, on bone metabolism. J Agric Food Chem.
57:7293–7297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JH, Jin H, Shim HE, Kim HN, Ha H and
Lee ZH: Epigallo-catechin-3-gallate inhibits osteoclastogenesis by
down-regulating c-Fos expression and suppressing the nuclear
factor-kappaB signal. Mol Pharmacol. 77:17–25. 2010. View Article : Google Scholar
|
|
39
|
Lee SH, Kim BJ, Choi HJ, et al:
(−)-Epigallocathechin-3-gallate, an aMPK activator, decreases
ovariectomy-induced bone loss by suppression of bone resorption.
Calcif Tissue Int. 90:404–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deeks ED and Perry CM: Zoledronic acid: A
review of its use in the treatment of osteoporosis. Drugs aging.
25:963–986. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang FL and Casey PJ: Protein
prenylation: Molecular mechanisms and functional consequences. Annu
Rev Biochem. 65:241–269. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tobiume H, Kanzaki S, Hida S, Ono T,
Moriwake T, Yamauchi S, Tanaka H and Seino Y: Serum bone alkaline
phosphatase isoenzyme levels in normal children and children with
growth hormone (GH) deficiency: A potential marker for bone
formation and response to GH therapy. J Clin Endocrinol Metab.
82:2056–2061. 1997.PubMed/NCBI
|
|
43
|
Rachner TD, Singh SK, Schoppet M, Benad P,
Bornhäuser M, Ellenrieder V, Ebert R, Jakob F and Hofbauer LC:
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio
in breast cancer cells. Cancer Lett. 287:109–116. 2010. View Article : Google Scholar
|
|
44
|
Zhou F, Zhou H, Wang T, Mu Y, Wu B, Guo
DL, Zhang XM and Wu Y: Epigallocatechin-3-gallate inhibits
proliferation and migration of human colon cancer SW620 cells in
vitro. Acta Pharmacol Sin. 33:120–126. 2012. View Article : Google Scholar
|
|
45
|
Oppenheimer SB: Cellular basis of cancer
metastasis: A review of fundamentals and new advances. Acta
Histochem. 108:327–334. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hiraga T, Williams PJ, Ueda A, Tamura D
and Yoneda T: Zoledronic acid inhibits visceral metastases in the
4T1/luc mouse breast cancer model. Clin Cancer Res. 10:4559–4567.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Orlando L, Cardillo A, Ghisini R, Rocca A,
Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E and
Colleoni M: Trastuzumab in combination with metronomic
cyclophosphamide and methotrexate in patients with HER-2 positive
metastatic breast cancer. BMC Cancer. 6:2252006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
de Weerdt O, van de Donk NW, Veth G, Bloem
AC, Hagenbeek A and Lokhorst HM: Continuous low-dose
cyclophosphamide-prednisone is effective and well tolerated in
patients with advanced multiple myeloma. Neth J Med. 59:50–56.
2001. View Article : Google Scholar : PubMed/NCBI
|
